Elevance Health (ELV) EBITDA (2009 - 2026)

Elevance Health (ELV) has reported EBITDA for 18 consecutive years, with $704.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 44.86% year-over-year to $704.0 million in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 20.1% increase from a year earlier, with the FY2025 full-year figure at $2.2 billion, up 6.97% from the prior year.
• EBITDA was $704.0 million for Q2 2026 at Elevance Health, down from $765.0 million in the prior quarter.
• Over five years, EBITDA peaked at $765.0 million in Q1 2026 and troughed at $360.0 million in Q1 2022.
• A 5-year average of $501.3 million and a median of $493.0 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA decreased 6.45% in 2025 and surged 44.86% in 2026, its largest moves.
• Over 5 years, EBITDA stood at $373.0 million in 2022, then soared by 41.82% to $529.0 million in 2023, then dropped by 0.38% to $527.0 million in 2024, then decreased by 6.45% to $493.0 million in 2025, then soared by 42.8% to $704.0 million in 2026.
• The last three EBITDA figures came in at $704.0 million (Q2 2026), $765.0 million (Q1 2026), and $493.0 million (Q4 2025), per Business Quant data.